Ustekinumab has two alternative drug maintenance intervals for inflammatory bowel disease (IBD), every 8 weeks (Q8W) and every 12 weeks (Q12W). The current study aimed at evaluating the comparative efficacy and safety of the two maintenance intervals in patients with IBD. A systematic search on PubMed, Web of Science, Cochrane Library, and EMBASE was carried out. The relative risk (RR) was pooled for efficacy and safety outcomes between the two intervals at various follow-up time points, categorized as short term (less than 44 weeks), medium term (about 92 weeks), and long term (about 152 weeks). A total of 14 studies with 1448 patients were included. Q8W didn't result in a remarkably higher proportion of clinical remission compared to Q12W at short term (RR, 0.99; 95% CI, 0.83-1.16), medium term (RR, 1.05; 95% CI, 0.91-1.20), and long term (RR, 1.07; 95% CI, 0.91-1.26). Similarly, no substantial differences exist at short term in clinical response (RR, 1.00; 95% CI, 0.85-1.17), endoscopic remission (RR, 0.97; 95% CI, 0.26-3.69), and histologic improvement (RR, 1.13; 95% CI, 0.93-1.36) between the two intervals. For safety outcomes, the RR values for any adverse events in the short, medium, and long term were 1.10 (95% CI, 1.00-1.21), 1.14 (95% CI, 1.08-1.20), and 1.12 (95% CI, 1.07-1.17) for Q8W versus Q12W. Finally, we conclude that ustekinumab maintenance therapy administered every 8 and 12 weeks showed similar effectiveness in achieving efficacy outcomes in IBD patients, and most safety outcomes were significantly better for Q12W during the maintenance phase.

中文翻译：

---

乌司奴单抗在炎症性肠病维持阶段不同间隔的有效性和安全性比较：系统评价和荟萃分析。

Ustekinumab 对于炎症性肠病 (IBD) 有两种替代药物维持间隔，每 8 周 (Q8W) 和每 12 周 (Q12W)。本研究旨在评估两种维持间隔对 IBD 患者的疗效和安全性比较。在 PubMed、Web of Science、Cochrane Library 和 EMBASE 上进行了系统检索。不同随访时间点的两个间隔之间的疗效和安全性结果的相对风险 (RR) 被汇总，分为短期（少于 44 周）、中期（约 92 周）和长期（约 152周）。总共纳入了 14 项研究，涉及 1448 名患者。与 Q12W 相比，Q8W 在短期（RR，0.99；95% CI，0.83-1.16）、中期（RR，1.05；95% CI，0.91-1.20）和长期（RR，1.07；95% CI，0.91-1.26）。同样，短期内临床反应（RR，1.00；95% CI，0.85-1.17）、内镜缓解（RR，0.97；95% CI，0.26-3.69）和组织学改善（RR，1.13；95% CI，0.85-1.17）方面不存在显着差异。两个区间之间的 95% CI，0.93-1.36）。对于安全性结果，短期、中期和长期任何不良事件的 RR 值分别为 1.10 (95% CI，1.00-1.21)、1.14 (95% CI，1.08-1.20) 和 1.12 (95% CI， 1.07-1.17) Q8W 与 Q12W。最后，我们得出的结论是，每 8 周和每 12 周进行一次乌特克单抗维持治疗在 IBD 患者中显示出相似的疗效，并且在维持阶段 Q12W 的大多数安全性结果明显更好。